NCT00857558

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 350 (actual)
• Sponsor: Kyowa Kirin Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, double-blind, placebo-controlled, group-comparison study to investigate the safety and efficacy of OPC-262 in patients with type 2 diabetes

Conditions

• Diabetes, Type 2

Interventions

Type	Name	Description
DRUG	saxagliptin	orally administration at 1 mg once a day for 12 weeks
DRUG	saxagliptin	orally administration at 2.5 mg once a day for 12 weeks
DRUG	saxagliptin	orally administration at 5 mg once a day for 12 weeks
DRUG	placebo	orally administration once a day for 12 weeks

Timeline

• Start date: 2009-01-01
• Primary completion: 2010-03-01
• Completion: 2010-05-01
• First posted: 2009-03-06
• Last updated: 2017-03-09

Locations

8 sites across 1 country: Japan